Deltex Medical Group plc (LON:DEMG), the medtech firm, has been granted a new patent for its combined blood flow and blood pressure monitor.
The granted coverage is for UK, Germany, France, Spain and Sweden.
Coverage in the USA has been 'allowed' at this stage and the company expects the US patent to be formally granted in the second half of the year.
Deltex shares fell 0.32p to 3.81p on the announcement, with some investors banking profits after last Friday’s announcement of the first sale of one Deltex’s surgical blood monitoring systems for veterinary use.
READ Deltex Medical makes first sale of blood monitor for vet use
The Aim-listed oesophageal Doppler monitoring specialist said the device filing covers the use of Doppler measurements of central blood flow, measured with either oesophageal or above the sternum (e.g. jugular vein) ultrasound probes, in conjunction with blood pressure signals whether measured in arteries, veins or by way of non invasive pressure cuffs placed on the arm or fingers.
The coverage also includes the combination of a venous oxygen saturation sensor with the flow and pressure measurements.
"This patent is very important. It underpins and protects our combination of Doppler ultrasound flow signals with blood pressure inputs on a single monitoring platform including the current CardioQ-ODM+ platform,” explained Ewan Phillips, chief executive officer of Deltex.
"Doing this offers us unique possibilities to advance haemodynamic monitoring. We recently received a €50,000 EU grant to support the clinical development of innovative new 'TruVue' graphical user interfaces which are driven by combining flow and pressure signals," he added.